Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001641172-25-003848
Filing Date
2025-04-11
Accepted
2025-04-11 16:30:35
Documents
23
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 formpre14a.htm   iXBRL PRE 14A 678110
2 formpre14a_001.jpg GRAPHIC 10758
3 formpre14a_002.jpg GRAPHIC 10758
4 formpre14a_003.jpg GRAPHIC 58474
5 formpre14a_004.jpg GRAPHIC 55200
6 formpre14a_005.jpg GRAPHIC 286421
7 formpre14a_006.jpg GRAPHIC 198187
  Complete submission text file 0001641172-25-003848.txt   2986918

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE tnfa-20241231.xsd EX-101.SCH 6529
9 XBRL DEFINITION FILE tnfa-20241231_def.xml EX-101.DEF 11755
10 XBRL LABEL FILE tnfa-20241231_lab.xml EX-101.LAB 67780
11 XBRL PRESENTATION FILE tnfa-20241231_pre.xml EX-101.PRE 44371
25 EXTRACTED XBRL INSTANCE DOCUMENT formpre14a_htm.xml XML 147222
Mailing Address 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY 10036 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-36268 | Film No.: 25832484
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)